Impact of Left Ventricular Function and Heart Failure Symptoms on Outcomes Post Ablation of Atrial Fibrillation in Heart Failure: CASTLE-AF Trial.


Journal

Circulation. Arrhythmia and electrophysiology
ISSN: 1941-3084
Titre abrégé: Circ Arrhythm Electrophysiol
Pays: United States
ID NLM: 101474365

Informations de publication

Date de publication:
10 2020
Historique:
pubmed: 10 9 2020
medline: 16 3 2021
entrez: 9 9 2020
Statut: ppublish

Résumé

Recent data demonstrate promising effects on left ventricular dysfunction and left ventricular ejection fraction (LVEF) improvement following ablation for atrial fibrillation (AF) in patients with heart failure. We sought to study the relationship between LVEF, New York Heart Association class on presentation, and the end points of mortality and heart failure admissions in the CASTLE-AF study (Catheter Ablation for Atrial Fibrillation With Heart Failure) population. Furthermore, predictors for LVEF improvement were examined. The CASTLE-AF patients with coexisting heart failure and AF (n=363) were randomized in a multicenter prospective controlled fashion to ablation (n=179) versus pharmacological therapy (n=184). Left ventricular function and New York Heart Association class were assessed at baseline (after randomization) and at each follow-up visit. In the ablation arm, a significantly higher number of patients experienced an improvement in their LVEF to >35% at the end of the study (odds ratio, 2.17; Compared with pharmacological treatment, AF ablation was associated with a significant improvement in LVEF, independent from the severity of left ventricular dysfunction. AF ablation should be performed at early stages of the patient's heart failure symptoms.

Sections du résumé

BACKGROUND
Recent data demonstrate promising effects on left ventricular dysfunction and left ventricular ejection fraction (LVEF) improvement following ablation for atrial fibrillation (AF) in patients with heart failure. We sought to study the relationship between LVEF, New York Heart Association class on presentation, and the end points of mortality and heart failure admissions in the CASTLE-AF study (Catheter Ablation for Atrial Fibrillation With Heart Failure) population. Furthermore, predictors for LVEF improvement were examined.
METHODS
The CASTLE-AF patients with coexisting heart failure and AF (n=363) were randomized in a multicenter prospective controlled fashion to ablation (n=179) versus pharmacological therapy (n=184). Left ventricular function and New York Heart Association class were assessed at baseline (after randomization) and at each follow-up visit.
RESULTS
In the ablation arm, a significantly higher number of patients experienced an improvement in their LVEF to >35% at the end of the study (odds ratio, 2.17;
CONCLUSIONS
Compared with pharmacological treatment, AF ablation was associated with a significant improvement in LVEF, independent from the severity of left ventricular dysfunction. AF ablation should be performed at early stages of the patient's heart failure symptoms.

Identifiants

pubmed: 32903044
doi: 10.1161/CIRCEP.120.008461
doi:

Substances chimiques

Anti-Arrhythmia Agents 0

Types de publication

Comparative Study Journal Article Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e008461

Auteurs

Christian Sohns (C)

Clinic for Electrophysiology, Herz- und Diabeteszentrum NRW, Ruhr-Universität Bochum, Bad Oeynhausen, Germany (C.S.).

Konstantin Zintl (K)

Department of Cardiology, Klinikum Coburg, Germany (K.Z., C.M., J.B.).

Yan Zhao (Y)

Department of Cardiology, Tulane University School of Medicine, New Orleans, LA (Y.Z., L.D., N.F.M.).

Lilas Dagher (L)

Department of Cardiology, Tulane University School of Medicine, New Orleans, LA (Y.Z., L.D., N.F.M.).

Dietrich Andresen (D)

Kardiologie an den Ev. Elisabeth-Kliniken, Berlin, Germany (D.A.).

Jürgen Siebels (J)

Electrophysiology Center Bremen, Germany (J.S.).

Karl Wegscheider (K)

Department of Medical Biometry and Epidemiology, University Medical Center Hamburg-Eppendorf, Germany (K.W., S.S.).

Susanne Sehner (S)

Department of Medical Biometry and Epidemiology, University Medical Center Hamburg-Eppendorf, Germany (K.W., S.S.).

Lucas Boersma (L)

Department of Cardiology, Antonius Ziekenhuis Nieuwegein, the Netherlands (L.B.).

Béla Merkely (B)

Department of Cardiology, Semmelweis Medical University, Budapest, Hungary (B.M.).

Evgeny Pokushalov (E)

State Research Institute of Circulation Pathology, Novosibirsk, Russia (E.P.).

Prashanthan Sanders (P)

Center for Heart Rhythm Disorders, University of Adelaide and Royal Adelaide Hospital, Australia (P.S.).

Heribert Schunkert (H)

Department of Cardiology, Deutsches Herzzentrum München, Munich, Germany (H.S.).

Dietmar Bänsch (D)

Clinic for Electrophysiology, KMG Klinikum, Güstrow, Germany (D.B.).

Christian Mahnkopf (C)

Department of Cardiology, Klinikum Coburg, Germany (K.Z., C.M., J.B.).

Johannes Brachmann (J)

Department of Cardiology, Klinikum Coburg, Germany (K.Z., C.M., J.B.).

Nassir F Marrouche (NF)

Department of Cardiology, Tulane University School of Medicine, New Orleans, LA (Y.Z., L.D., N.F.M.).

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH